Previous 10 | Next 10 |
KNOXVILLE, TN, March 23, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed US patent application 16/412,872, which covers the use of intralesional (aka intratumoral) PV-10, an injectable formulation of Pro...
KNOXVILLE, TN, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that H. Lee Moffitt Cancer Center (Moffitt) has released a manuscript preprint describing how investigational autolytic cancer immunotherapy PV-10, an injectable formulation of Provectus’ proprie...
29% ORR (7% CR) and 57% DCR (RECIST 1.1) 75% ORR in anti-PD-1-refractory patients 56% DCR (11% CR) in patients refractory to anti-CTLA-4 and anti-PD-1 combination therapy Presentation delivered by Moffitt’s Jonathan Zager, MD KNOXVILLE, TN, Dec. 07, 2020 (GLOBE NE...
KNOXVILLE, TN, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that H. Lee Moffitt Cancer Center (Moffitt) presented non-clinical data from ongoing research on investigational autolytic cancer immunotherapy PV-10, an injectable formulation of Provectus' proprietary...
KNOXVILLE, TN, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from the Company's ongoing Phase 1b/2 study of autolytic cancer immunotherapy PV-10, an injectable formulation of Provectus' proprietary small molecule rose bengal disodium (RBD), in combinati...
KNOXVILLE, TN, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that H. Lee Moffitt Cancer Center will present non-clinical data from ongoing research on investigational autolytic cancer immunotherapy PV-10, an injectable formulation of Provectus' proprietary rose b...
Provectus ([[PVCT]] -2.9%) has completed enrollment of 12 patients for its Phase 1 of cancer immunotherapy PV-10, an injectable formulation of its proprietary rose bengal disodium, for the treatment of symptomatic neuroendocrine tumors metastatic to the liver, refractory to somatostatin ...
Company plans to seek end-of-phase meeting with Australia’s Therapeutic Goods Administration in Q1 2021 KNOXVILLE, TN, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced the completion of enrollment of 12 patients into the Company’s Phase 1 stu...
Complete response of all injected lesions Regression of non-injected inguinal node, lung, and brain metastases Expanded data set of trial subject provided KNOXVILLE, TN, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today highlighted the clinical outcome of a ...
Near-resolution of tumor burden, including extensive visceral hepatic disease Expanded data set of trial subject provided KNOXVILLE, TN, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today highlighted the clinical outcome of a Stage IV M1c patient (Subject 0112) in ...
News, Short Squeeze, Breakout and More Instantly...
Provectus Biopharmaceuticals Inc Company Name:
PVCT Stock Symbol:
OTCMKTS Market:
Provectus Biopharmaceuticals Inc Website:
KNOXVILLE, Tenn., June 13, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today that its 2024 annual stockholder meeting (the “2024 Annual Meeting”), including meeting activities and ...
Accelerates wound closure and improves wound healing KNOXVILLE, TN, May 21, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that non-clinical data on Provectus’s proprietary, pharma...
PDAT clinical outcomes for infectious keratitis from Brazil and Mexico KNOXVILLE, TN, May 14, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that clinical and non-clinical data on rose be...